.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,332,481

« Back to Dashboard

Claims for Patent: 7,332,481

Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (Collegeville, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan (Collegeville, PA), Price; Alan T. (Collegeville, PA), Shaw; Antony N. (Collegeville, PA), Visonneau; Sophie (San Diego, PA), Wiggall; Kenneth (Collegeville, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:11/620,260
Patent Claims: 1. A method of treating thrombocytopenia in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound of Formula (I): ##STR00013## wherein: R, R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6alkyl, --(CH.sub.2).sub.pOR.sup.4, --C(O)OR.sup.4, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, --S(O).sub.nR.sup.4, cycloalkyl, --NR.sup.5R.sup.6, protected --OH, --CONR.sup.5R.sup.6, phosphonic acid, sulfonic acid, phosphinic acid, --SO.sub.2NR.sup.5R.sup.6, and a heterocyclic methylene substituent as represented by Formula (III), ##STR00014## where, p is 0-6, n is 0-2, V, W, X and Z are each independently selected from O, S and NR.sup.16, where R.sup.16 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, R.sup.4 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, and R.sup.5 and R.sup.6 are each independently selected from hydrogen, alkyl, substituted alkyl, C.sub.3-6cycloalkyl, and aryl, or R.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen; m is 0-6; and AR is a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and containing from one to three heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, --C(O)OR.sup.4, --C(O)NR.sup.10R.sup.11, --S(O).sub.2NR.sup.10R.sup.11, --S(O).sub.nR.sup.4 and protected --OH, where n is 0-2, R.sup.4 is hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, and R.sup.10 and R.sup.11 are independently hydrogen, cycloalkyl, C.sub.1-C.sub.12aryl, substituted cycloalkyl, substituted C.sub.1-C.sub.12aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, --C(O)OR.sup.4, --S(O).sub.nR.sup.4, --C(O)NR.sup.4R.sup.4, --S(O).sub.2NR.sup.4R.sup.4, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected --OH, or R.sup.10 and R.sup.11 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where R.sup.4 is as described above and n is 0-2; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof; provided that at least one of R, R.sup.1, R.sup.2 and R.sup.3 is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III).

2. The method to claim 1 wherein, when a single substituent is present on a substituted aryl group defined by any of R, R.sup.1, R.sup.2 and R.sup.3, said substituent is selected from the group consisting of: --CO.sub.2R.sup.20 aryl --C(O)NHS(O).sub.2R.sup.20--NHS(O).sub.2R, hydroxyalkyl, alkoxy, --C(O)NR.sup.21R.sup.22, acyloxy, amino, N-acylamino, hydroxy --(CH.sub.2).sub.gC(O)OR.sup.8--S(O).sub.nR.sup.8, nitro, tetrazole, cyano, oxo, halogen, trifluoromethyl, protected --OH and a heterocyclic methylene substituent as represented by Formula (III), ##STR00015## where g is 0-6; R.sup.8 is hydrogen or alkyl; R.sup.20 is selected form hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; R.sup.21 and R.sup.22 are independently selected from hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; V, W, X and Z are each independently selected from O, S, and NR.sup.16, where R.sup.16 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl; and n is 0-2.

3. The method of claim 1 wherein the administered compound is a compound of the Formula (II): ##STR00016## wherein: R, R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6alkyl, --(CH.sub.2).sub.pOR.sup.4, --C(O)OR.sup.4, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, --S(O).sub.nR.sup.4, cycloalkyl, --NR.sup.5R.sup.6, protected --OH, --CONR.sup.5R.sup.6, phosphonic acid, sulfonic acid, phosphinic acid, --SO.sub.2NR.sup.5R.sup.6, and a heterocyclic methylene substituent as represented by Formula (III), ##STR00017## where p is 0-6, n is 0-2, V, W, X and Z are each independently selected from O, S, and NR.sup.16, where R.sup.16 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, R.sup.4 is hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, and R.sup.5 and R.sup.6 are each independently selected from hydrogen, alkyl, substituted alkyl, C.sub.3-6cycloalkyl, and aryl, or R.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen; R.sup.15 is selected from the group consisting of alkyl, C.sub.1-C.sub.12aryl, hydroxy, alkoxy, substituted alkyl, substituted C.sub.1-C.sub.12aryl and halogen; m is 0-6; and Y is selected from alkyl, substituted alkyl and a cyclic or polycyclic aromatic ring containing from 3 to 14 carbon atoms and optionally containing from one to three heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, C.sub.1-C.sub.12aryl, substituted cycloalkyl, substituted C.sub.1-C.sub.12aryl, hydroxy, aryloxy, alkoxy, cycloalkyl, nitro, cyano, halogen and protected --OH; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof; provided that at least one of R, R.sup.1, R.sup.2 and R.sup.3 is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III).

4. The method of claim 3 wherein, when a single substituent is present on a substituted aryl group defined by any of R, R.sup.1, R.sup.2 and R.sup.3, said substituent is selected from the group consisting of: --CO.sub.2R.sup.20, aryl, --C(O)NHS(O).sub.2R.sup.20, --NHS(O).sub.2R.sup.20, hydroxyalkyl, alkoxy, --C(O)NR.sup.21R.sup.22, acyloxy, amino, N-acylamino, hydroxy, --(CH.sub.2).sub.gC(O)OR.sup.8, --S(O).sub.nR.sup.8, nitro, tetrazole, cyano, oxo, halogen, trifluoromethyl, protected --OH and a heterocyclic methylene substituent as represented by Formula (III), ##STR00018## where g is 0-6; R.sup.8 is hydrogen or alkyl; R.sup.20 is selected form hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; R.sup.21 and R.sup.22 are independently selected from hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; V, W, X and Z are each independently selected from O, S, and NR.sup.16, where R.sup.16 is selected from: hydrogen, alkyl, cycloakyl, C.sub.1-C.sub.12aryl, substituted alkyl substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl; and n is 0-2.

5. The method of claim 3 wherein the compound administered is a compound represented by Formula (II) wherein: either: R is a substituted aryl; and R.sup.1 is hydrogen; or: R is hydrogen; and R.sup.1 is a substituted aryl; and in either case: R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, cycloalkyl, phosphonic acid, phosphinic acid and sulfonic acid; R.sup.15 is selected from the group consisting of alkyl, substituted alkyl, C.sub.1-C.sub.12aryl, alkoxy and halogen; m is 0-4; and Y is selected from, phenyl, pyridinyl and pyrimidinyl, where the phenyl, pyridinyl and pyrimidinyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C.sub.1-C.sub.12aryl, substituted C.sub.1-C.sub.12aryl, alkoxy and halogen; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof.

6. The method of claim 5 wherein, when a single substituent is present on a substituted aryl group defined by any of R, R.sup.1, R.sup.2 and R.sup.3, said substituent is selected from the group consisting of: --CO.sub.2R.sup.20, aryl, --C(O)NHS(O).sub.2R.sup.20, --NHS(O).sub.2R.sup.2, hydroxyalkyl, alkoxy, --C(O)NR.sup.21R.sup.22, acyloxy, amino, N-acylamino, hydroxy --(CH.sub.2).sub.gC(O)OR.sup.8, --S(O).sub.nR.sup.8, nitro, tetrazole, cyano, oxo, halogen, trifluoromethyl protected --OH and a heterocyclic methylene substituent as represented by Formula (III), ##STR00019## where g is 0-6; R.sup.8 is hydrogen or alkyl: R.sup.20 is selected form hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; R.sup.21 and R.sup.22 are independently selected from hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl; V, W, X and Z are each independently selected from O, S, and NR.sup.16, where R.sup.16 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl substituted cycloalkyl and substituted C.sub.1-C.sub.12ary; and n is 0-2.

7. The method of claim 1 wherein the compound is selected from the group consisting of: 4'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-3'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-5'-chloro-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-5'-chloro-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro- pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-5'-fluoro-2'-hydroxybiphenyl-3-carboxylic acid; 7-({N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxyphenyl)quinolin-4[1H]-one-3-carboxylic acid; 7-({N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxyphenyl)quinolin-4[1H]-one-3-carboxylic acid; 3-Aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-5-carboxylic acid; 3-Aza-3'-(N'-[1-{3-methyl-[4-(1-methylethyl)phenyl]-5-oxo-1,5-dihydropyra- zol-4-ylidene}hydrazino)-2'-hydroxybiphenyl-5-carboxylic acid; 3-Aza-3'-{N'-[1-(4-tertbutylphenyl-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-5-carboxylic acid; 5'-Chloro-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazo- l-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3,5-dioxo-1,5-dihydropyrazol-4-ylidene]hyd- razino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(2-Ethoxy-2-oxoethyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylide- ne]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-4'-(tetrazol-5-yl)biphenyl; 3'-(N'-{1-[2-(N-tert-butyl)amino-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydropy- razol-4-ylidene} hydrazino)-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-Chloro-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 5-chloro-3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2-hydroxy-4'-(tetrazol-5-yl)biphenyl; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3,5-dicarboxylic acid; 3-Aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-5-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-4-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methoxy-5-oxo-1,5-dihydropyrazol-4-ylide- ne]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-methoxyphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]h- ydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; (3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxy-3'-biphenyl)-1,1,1,-trifluoromethanesulfonamide; 3'-{N'-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(3-trifluoromethylphenyl)-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 8-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino} quinolin-4[1H]-one-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-N-methylcarboxamidolphenyl)-1,5-dihydropyrazo- l-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; N-[1-(3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-yl)methanoyl]methanesulfonamide; 3'-{N'-[3-methyl-5-oxo-1-phenyl-1,5-dihydropyrazol-4-ylidene]hydrazino}-2- '-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-1-(4-methylphenyl)-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-chlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethoxyphenyl)-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-ethoxy-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-{1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-5-oxo-1,5-dihydropyrazo- l-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-tert-butyl-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-1-(4-methyl-2,3,5,6-tetrafluorophenyl)-5-oxo-1,5-dihydro- pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-fluoro-3-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-phenyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-phenyl-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-methoxy-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-ethoxy-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-5-oxo-1,5-dihydropyrazol- -4-ylidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(4-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hyd- razino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(4-fluoro-3-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(pyridin-4-yl-5-oxo-1,5-dihydropyrazol-4- -ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-pyridin-4-yl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-pyridin-2-yl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(pyridin-2-yl-5-oxo-1,5-dihydropyrazol-4- -ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3-fluoro-4-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3-fluoro-4-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylpyrimidin-2-yl)-1,5-dihydropyr- azol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-N-tert-butoxycarbonylamino-3-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-ox- o-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxybiphenyl; 3'-amino-3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2-hydroxybiphenyl; 3-{N'-[1-(3-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hyd- razino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[3-methyl-5-oxo-1-(2,3,4,5,6-pentafluorophenyl)-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[3-methyl-5-oxo-1-(2,3,4,5,6-pentafluorophenyl)-1,5-dihydropyrazol- -4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-difluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methoxymethyl-5-oxo-1,5-dihydropyrazol-4- -ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-methoxymethyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-difluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-trifluoromethyl-1,5-dihydropyrazol- -4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-6-fluoro-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-propyl-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-propyl-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(1-methyl-1 H-pyrrol-3-yl)-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybi- phenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-(1-methyl-1H-pyrrol-3-yl)-5-oxo-1,5-dihyd- ropyrazol-4-ylidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-furan-2-yl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-furan-2-yl-5-oxo-1,5-dihydropyrazol-4-yli- dene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; N-(2'-hydroxy-3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethyl-phenyl)-1,5-dih- ydro-pyrazol-4-ylidene]hydrazino}biphenyl-3-yl)-1,1,1-trifluoromethanesulf- onamide; N-(2'-hydroxy-3'-{N'-[1-(3-fluoro-4-methylphenyl)-3-methyl-5-oxo-- 1,5-dihydro-pyrazol-4-ylidene]hydrazino}biphenyl-3-yl)-1,1,1-trifluorometh- anesulfonamide; N-(2'-hydroxy-3'-{N'-[1-(4-fluoro-3-methylphenyl)-3-methyl-5-oxo-1,5-dihy- dro-pyrazol-4-ylidene]hydrazino} biphenyl-3-yl)-1,1,1-trifluoromethanesulfonamide; N-(2'-hydroxy-3'-{N'-[1-(3,4-difluorophenyl)-3-methyl-5-oxo-1,5-dihydro-p- yrazol-4-ylidene]hydrazino} biphenyl-3-yl)-1,1,1-trifluoromethanesulfonamide; N-(3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylid- ene]hydrazino}-2'-hydroxybiphenyl-3-yl)guanidine; 3'-{N'-[1-(3,4-dimethylphenyl)-3-ethyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-ethyl-5-oxo-1,5-dihydropyrazol-4-ylidene]- hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-thien-2-yl-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-cyclopropyl-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-thiazol-2-yl-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazi- no}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(1-methylethyl)-5-oxo-1,5-dihydropyrazol- -4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-(benzyloxymethyl)-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyraz- ol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-ethyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[-1-(3,4-dimethylphenyl)-3-hydroxymethyl-5-oxo-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-benzyloxymethyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropy- razol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[-1-(3,4-dimethylphenyl)-3-methylsulfanylmethyl-5-oxo-1,5-dihydrop- yrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[-1-(3,4-dimethylphenyl)-5-oxo-3-thiophen-3-yl-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[5-oxo-1-(4-trifluoromethylphenyl)-3-thiophen-3-yl-1,5-dihydropyra- zol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[5-oxo-1-(4-trifluoromethylphenyl)-3-methylsulfanylmethyl-1,5-dihy- dropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; N-(3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-yl)methanesulfonamide; 3'-[N'-(1-benzo[1,3]dioxol-5-yl-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylide- ne)hydrazino]-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,5-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-4'-hydroxybiphenyl-4-carboxylic acid; 3'-{N'-[1-(3-chloro-4-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-4'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-phosphonic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3,4-dicarboxylic acid; 2',6-dihydroxy-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydrop- yrazol-4-ylidene]hydrazino}biphenyl-3-carboxylic acid; 4-aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-5-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-sulfonic acid; and 5-(3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yli- dene]hydrazino}-2'-hydroxybiphenyl-3-ylmethylene)thiazolidine-2,4-dione; and or a pharmaceutically acceptable salt, hydrate, solvaten or esterthereof.

8. The method of claim 1 wherein the compound is administered orally.

9. The method of claim 1 wherein the compound is administered parenterally.

10. A method of claim 1 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine, and an interleukin or cytokine receptor agonist or antagonists.

11. The method of claim 10 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SCF, FLT3 ligand, LIF, IL-3, IL-6, IL-1, NESP, SD-01, IL-8, and IL-5.

12. A method of claim 1 wherein said thrombocytopenia is due to myelosuppression caused by chemotherapy or radiation therapy.

13. A method of claim 1 wherein said thrombocytopenia is due to an organ transplant.

14. A method of claim 1 wherein said thrombocytopenia is due to bone marrow, stem cell, or liver transplant.

15. A method of claim 1 wherein said thrombocytopenia is due to idiopathic thrombocytopenia purpura (ITP).

16. A method of claim 1 wherein said thrombocytopenia is due to myelodysplastic syndromes (MDS), aplastic anemia or leukemia.

17. A method of claim 1 wherein said thrombocytopenia is due to viral, fungal, microbial or parasitic infection.

18. A method of claim 1 wherein said thrombocytopenia is due to liver dysfunction.

19. A method of claim 1 wherein said thrombocytopenia is due to surgical procedures.

20. A method of claim 1 wherein said thrombocytopenia is due to treatment with antiviral or antibiotic agents.

21. A method of treating thrombocytopenia in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound selected from: 4'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-3'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-5'-chloro-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-5'-chloro-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro- pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 2-Aza-3'-{N'-[1-(3,4-dimethylphenyl-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxy-5'-methylbiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]- hydrazino}-5'-fluoro-2'-hydroxybiphenyl-3-carboxylic acid; 7-({N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxyphenyl)quinolin-4[1H]-one-3-carboxylic acid; 7-({N'-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxyphenyl)quinolin-4[1H]-one-3-carboxylic acid; 3-Aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-5-carboxylic acid; 3-Aza-3'-(N'-[1-{3-methyl-[4-(1-methylethyl)phenyl]-5-oxo-1,5-dihydropyra- zol-4-ylidene}hydrazino)-2'-hydroxybiphenyl-5-carboxylic acid; 3-Aza-3'-{N'-[1-(4-tertbutylphenyl-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-5-carboxylic acid; 5'-Chloro-3'-{N'-{[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyraz- ol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3,5-dioxo-1,5-dihydropyrazol-4-ylidene]hyd- razino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(2-Ethoxy-2-oxoethyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylide- ne]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-4'-(tetrazol-5-yl)biphenyl; 3'-{N'-1-[2-(N-tert-butyl)amino-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydropyr- azol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid: and 3'-{N'-[3-Chloro-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof.

22. The method of claim 1 wherein R is a phenyl substituted with --(CH.sub.2).sub.gC(O)OR.sup.8, where --(CH.sub.2).sub.g represents a linear or branched, saturated or unsaturated hydrocarbon chain containing 0 to 6 carbons and R.sup.8 is hydrogen or alkyl.

23. A method of treating thrombocytopenia in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound of Formula (V): ##STR00020## wherein: R, R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.pOR.sup.4, --C(O)OR.sup.4, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, --S(O).sub.nR.sup.4, cycloalkyl, --NR.sup.5R.sup.6, protected --OH, --CONR.sup.5R.sup.6, phosphonic acid, sulfonic acid, phosphinic acid and --SO.sub.2NR.sup.5R.sup.6, where, p is 0-6, n is 0-2, R.sup.4 is selected from: hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl, and R.sup.5 and R.sup.6 are each independently selected from hydrogen, alkyl, substituted alkyl, C.sub.3-6cycloalkyl, and aryl, or R.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen; m is 0-6; and AR is a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, --C(O)OR.sup.4, --C(O)NR.sup.10R.sup.11, --S(O).sub.2NR.sup.10R.sup.11, --S(O).sub.nR.sup.4 and protected --OH, where n is 0-2, R.sup.4 is hydrogen, alkyl, cycloalkyl, C.sub.1-C.sub.12aryl, substituted alkyl, substituted cycloalkyl and substituted C.sub.1-C.sub.12aryl; and R.sup.10 and R.sup.11 are independently hydrogen, cycloalkyl, C.sub.1-C.sub.12aryl, substituted cycloalkyl, substituted C.sub.1-C.sub.12aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, --C(O)OR.sup.4, --S(O).sub.nR.sup.4, --C(O)NR.sup.4R.sup.4, --S(O).sub.2NR.sup.4R.sup.4, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected --OH, or R.sup.10 and R.sup.11 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where R.sup.4 is as described above and n is 0-2; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof; provided that at least one of R, R.sup.1, R.sup.2 and R.sup.3 is a substituted aryl group.

24. The method to claim 23 wherein, when a single substituent is present on a substituted aryl group defined by any of R, R.sup.1, R.sup.2 and R.sup.3, said substituent is selected from the group consisting of: --CO.sub.2R.sup.20, aryl, --C(O)NHS(O).sub.2R.sup.20, --NHS(O).sub.2R.sup.20, hydroxyalkyl, alkoxy, --C(O)NR.sup.21R.sup.22, acyloxy, amino, N-acylamino, hydroxy, --(CH.sub.2).sub.gC(O)OR.sup.8, --S(O).sub.nR.sup.8, nitro, tetrazole, cyano, oxo, halogen, trifluoromethyl and protected --OH, where g is 0-6, R.sup.8 is hydrogen or alkyl, R.sup.20 is selected form hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl, and R.sup.21 and R.sup.22 are independently selected form hydrogen, C.sub.1-C.sub.4alkyl, aryl and trifluoromethyl, and n is 0-2.

25. The method of claim 23 wherein R is a phenyl substituted with --(CH.sub.2).sub.gC(O)OR.sup.8, where --(CH.sub.2).sub.g represents a linear or branched, saturated or unsaturated hydrocarbon chain containing 0 to 6 carbons and R.sup.8 is hydrogen or alkyl.

26. The method of claim 1 wherein the compound is selected from: 5-chloro-3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-- 4-ylidene]hydrazino}-2-hydroxy-4'-(tetrazol-5-yl)biphenyl; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3,5-dicarboxylic acid; 3-Aza-3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxy-5'-methylbiphenyl-5-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-4-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methoxy-5-oxo-1,5-dihydropyrazol-4-ylide- ne]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-methoxyphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]h- ydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-trifluoromethanesulfonamidobiphenyl; 3'-{N'-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(3-trifluoromethylphenyl)-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 8-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino} quinolin-4[1H]-one-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-N-methylcarboxamidolphenyl)-1,5-dihydropyrazo- l-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; N-[1-(3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-yl)methanoyl]methanesulfonamide; 3'-{N'-[3-methyl-5-oxo-1-phenyl-1,5-dihydropyrazol-4-ylidene]hydrazino}-2- '-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-1-(4-methylphenyl)-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-chlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hy- drazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethoxyphenyl)-1,5-dihydropyrazol-4-- ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-ethoxy-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-5-oxo-1,5-dihydropyrazo- l-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-tert-butyl-1-(3,4-dimethylphenyl)-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[3-methyl-1-(4-methyl-2,3,5,6-tetrafluorophenyl)-5-oxo-1,5-dihydro- pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(4-fluoro-3-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethylphenyl)-3-phenyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-5-oxo-3-phenyl-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-methoxy-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-ethoxy-5-oxo-1,5-dihydropyrazol-4-ylidene- ]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-5-oxo-1,5-dihydropyrazol- -4-ylidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(4-fluorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hyd- razino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(4-fluoro-3-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylphenyl)-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(pyridin-4-yl-5-oxo-1,5-dihydropyrazol-4- -ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3,4-dimethylphenyl)-3-pyridin-4-yl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3-{N'-[1-(3,4-dimethylphenyl)-3-pyridin-2-yl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3,4-dimethylphenyl)-3-(pyridin-2-yl-5-oxo-1,5-dihydropyrazol-4- -ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-{N'-[1-(3-fluoro-4-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yl- idene]hydrazino}-2-hydroxy-3'-tetrazol-5-ylbiphenyl; 3'-{N'-[1-(3-fluoro-4-methylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-y- lidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; and 3'-{N'-[3-methyl-5-oxo-1-(4-trifluoromethylpyrimidin-2-yl)-1,5-dihydropyr- azol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc